To Top

Community

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Contribution
Appointment

Perrigo Appoints James Dillard To Role Of Chief Scientific Officer

PR-M01-19-NI-044
Hematology

Newly Discovered Phagocyte Plays Role in Autoimmune Disease

PR-M01-19-NI-044
Investment

CVS Health Announces $100 Million Community Commitment Following Acquisition Of Aetna

PR-M01-19-NI-044
Oncology Drugs

China Cancer Drugs Market 2018-2024: Rising Demand of Targeted Drug Therapy and the Patent Expiration of Key Cancer Drugs

PR-M01-19-NI-044
Lyophilization

Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI

PR-M01-19-NI-052
Robotics

The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028

PR-M01-19-NI-043
Expression System

Fujifilm Announces the Launch of Its Next Generation Apollo™ X Advanced Mammalian Expression System

PR-M01-19-NI-042
Myopia

SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

PR-M01-19-NI-040
Precision Diagnostics

Pillar Biosciences Enters Strategic Partnership with China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

PR-M01-19-NI-041
Partnership

Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India

PR-M01-19-NI-039
Investment

New Opioid-alternative Raises $3.25 Million for Phase I Trials

PR-M01-19-NI-037
Announcement

A Path Forward for Increasing Kidney Transplantation

PR-M01-19-NI-036
ALS Research

Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression

PR-M01-19-NI-035
Hematology/Oncology

Blood Cancer Therapeutics: Global Markets to 2023

PR-M01-19-NI-034
Medical Device

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

PR-M01-19-NI-033
RNA Splicing

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

PR-M01-19-NI-032
Immuno-oncology

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PR-M01-19-NI-031
Leadership

AstraZeneca Announces Organizational Changes

PR-M01-19-NI-029
Approval

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

PR-M01-19-NI-028
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

PAO-M01-19-NI-012
R&D

Allergan Establishes R&D Group in Massachusetts

PAO-M01-19-NI-010
Facility

DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

PR-M01-19-NI-036
Realignment

Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities

PR-M01-19-NI-024
Immuno-Oncology

PrimeVax Immuno-Oncology Receives IND Permission From FDA

PR-M01-19-NI-026
Investment

Vedanta Increases Investment

PAO-M01-19-NI-004
Drug Pricing

Drug Companies Raise Prices to Start New Year

PAO-M01-19-NI-003
Acquisition

Neogen Acquires Canadian Animal Genomics Laboratory

PR-M01-19-NI-011
Financial Results

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019

PR-M01-19-NI-010
J.P. Morgan Healthcare Conference

Grace Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR-M01-19-NI-009
Immuno-oncology

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

PR-M01-19-NI-023
FDA

PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration

PR-M01-19-NI-016
Drug Development

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

PR-M01-19-NI-013
Acquisition

Rentschler Biopharma Completes Acquisition of U.S. Manufacturing Site

PR-M01-19-NI-021
Announcement

Baltimore Biotech Earns International Recognition for Advanced Development and Manufacturing Facility

PR-M01-19-NI-020
Appointment

Brammer Bolsters Leadership Team and Announces Chief Quality Officer

PR-M01-19-NI-019
M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

PR-M01-19-NI-017
Announcement

Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR-M01-19-NI-006
Investment

China SXT Pharmaceuticals, Inc. Announces First Closing of Initial Public Offering

PR-M01-19-NI-007
Investment

Connect Biopharmaceuticals Completes $55 Million Series B Financing to Accelerate Clinical Development of Novel Immune Modulators

PR-M01-19-NI-005
Leadership

AbbVie Announces Executive Leadership Changes

PR-M01-19-NI-003
Biosimilar

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

PR-M01-19-NI-002
Market Prediction

Pneumatic Nebulizers Market Will Surge at 5.3% CAGR to Hit $875 Mn by 2024: Global Market Insights, Inc.

PR-M12-18-NI-083
Financing

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

PR-M12-18-NI-081
New Facility

Pall Opens Center of Excellence in Shanghai

PR-M12-18-NI-080
Advisory Board

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

PR-M12-18-NI-079
Acquisition

Bruker Completes the Acquisition of Alicona Imaging GmbH

PR-M12-18-NI-082
Drug Development

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

PR-M12-18-NI-076
Inflammation

IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body

PR-M12-18-NI-072
Appointment

AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

PR-M12-18-NI-074
Biomanufacturing Facility

LakePharma Announces its cGMP MicroBiomanufacturing Center is Now Operational

PR-M12-18-NI-073
Biologics

Rentschler Expands Capabilities in Biologics Contract Manufacturing

PAO-M12-18-NI-012
Biologics Manufacturing

AGC Triples U.S. Biopharmaceutical Production Capacity

PR-M12-18-NI-066
Market Prediction

Emerging Medical Device Market Expected to Exceed $400 Billion by 2023

PR-M12-18-NI-065
Patient Adherence

Sempre Health and UPMC Health Plan Expand Program that Improves Affordability and Adherence for Critical Medications

PR-M12-18-NI-064
Collaboration

Marken and TrakCel Collaborate to Serve Cell and Gene Trials

PR-M12-18-NI-087
Medical Device

Statement from Jeff Shuren, Director of the CDRH, on Updated Safety Communication About Rates of Duodenoscope Contamination from Preliminary Postmarket Data

PR-M12-18-NI-062
Surgical Robots

The global Surgical Robots Market is Projected to Reach 6.5 billion by 2023 from USD 3.9 billion in 2018 at a CAGR of 10.4%

PR-M12-18-NI-061
Public Offering

Biohaven Announces Proposed Public Offering of Common Shares

PR-M12-18-NI-060
Clinical Trial Patient Populations

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

PR-M12-18-NI-059
Cell Expansion

Cell Expansion Market to Reach US $26 Billion by 2024, Says TMR

PR-M12-18-NI-058
Investment

GenEdit Closes $8.5 million Series Seed Financing

PR-M12-18-NI-056
Approval

World-first Approval For Multiple Myeloma Drug APLIDIN(R)

PR-M12-18-NI-055
Drug Development

Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

PR-M12-18-NI-054
Acquisition

Therapix Biosciences Provides Update Regarding FSD Acquisition

PR-M12-18-NI-052
Presentation

Abbott to Present at J.P. Morgan Healthcare Conference

PR-M12-18-NI-051
Appointment

BiomX Appoints Sailaja Puttagunta as Chief Medical Officer

PR-M12-18-NI-048
FDA

XOSPATA® (gilteritinib) Available at Biologics by McKesson

PR-M12-18-NI-045
Pricing

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Expansion

NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem

PR-M12-18-NI-043
Financing

Impel NeuroPharma Closes $67.5 Million Series D Financing

PR-M12-18-NI-040
Immuno-Oncology

Immuno-oncology Development Trends and Opportunities

PR-M12-18-NI-038
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037
Financial Results

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

PR-M12-18-NI-036
Appointment

Roche Exec Moves to Gilead

PAO-M12-18-NI-010
Expansion

Investor Group Purchases 110-Acre Pharmaceutical Campus in Huntsville, Alabama

PR-M12-18-NI-047
M&A

Histo-Scientific Research Laboratories and Vet Path Services Merge

PR-M12-18-NI-046
Gene and Cell Therapy

PPD Expands GMP Lab Testing Capabilities for Biologics

PR-M12-18-NI-035
FDA Acceptance

FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis

PR-M12-18-NI-030
FDA Approval

Olympus Spiration® Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema

PR-M12-18-NI-029
Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028
Appointment

Sartorius Supervisory Board Appoints Two New Executive Board Members

PR-M12-18-NI-027
License Agreement

Ablexis Announces Licensing Agreement with Allogene Therapeutics

PR-M12-18-NI-026
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025
Obesity

The Anti-Obesity Drugs Market Will Register a CAGR of Almost 8% by 2023

PR-M12-18-NI-024
Chronic Migraine

Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.

PR-M12-18-NI-023
Phase 3

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

PR-M12-18-NI-019
Oncology

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR

PR-M12-18-NI-017
Bayer

Cutbacks and Divestitures Planned at Bayer

PAO-M12-18-NI-004
Alzheimer's Disease

Ocular Technology Provides Early Detection of Alzheimer's Disease

PR-M12-18-NI-014
Immunotherapy

Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche

PR-M12-18-NI-012
Cystic Fibrosis

Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

PR-M12-18-NI-013
ADC

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

PR-M12-18-NI-010
Market Prediction

The Global Single-Use Bioprocessing Mmarket is Anticipated to Reach Revenues of Approximately $7 Billion by 2024

PR-M12-18-NI-009
Stem Cells

Platelets Grown from Stem Cells May be Alternative to Donated Platelets

PR-M12-18-NI-006